title: Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
abstract: There have been multiple separate outbreaks of Bluetongue (BT) disease of ruminants in Europe since 1998, often entering via the Mediterranean countries of Italy, Spain and Greece. BT is caused by an orbivirus, Bluetongue virus (BTV), a member of the family Reoviridae. BTV is a non-enveloped double-capsid virus, which encodes 7 structural proteins (VP1-VP7) and several non-structural proteins (NS1, NS2, NS3/3a and NS4) from ten double-stranded RNA segments of the genome. In this report, we have prepared BTV virus-like particles (VLPs, composed of VP2, VP3, VP5 and VP7) and sub-viral, inner core-like particles (CLPs, VP3 and VP7) using a recombinant baculovirus expression system. We compared the protective efficacy of VLPs and CLPs in sheep and investigated the importance of geographical lineages of BTV in the development of vaccines. The Greek crossbred Karagouniko sheep, which display mild to sub-clinical BT, were vaccinated with VLPs or CLPs of BTV-1, derived from western lineage and were challenged with virulent BTV-1 from an eastern lineage. All VLP-vaccinated animals developed a neutralising antibody response to BTV-1 from both lineages prior to challenge. Moreover, post-challenged animals had no clinical manifestation or viraemia and the challenged virus replication was completely inhibited. In contrast, CLP-vaccinated animals did not induce any neutralising antibody response but developed the group specific VP7 antibodies. CLPs also failed to prevent the clinical manifestation and virus replication, but in comparison to controls, the severity of disease manifestation and viraemia was mitigated. The data demonstrated that the outer capsid was essential for complete protection, while the geographical origin of the BTV was not critical for development of a serotype specific vaccine.
authors.affiliation: Department of Infectious Diseases, London School of Hygiene and Tropical Medicine, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Stewart
authors.forename: C I
authors.initials: CI
authors.lastname: Dovas
authors.forename: E
authors.initials: E
authors.lastname: Chatzinasiou
authors.forename: T N
authors.initials: TN
authors.lastname: Athmaram
authors.forename: M
authors.initials: M
authors.lastname: Papanastassopoulou
authors.forename: O
authors.initials: O
authors.lastname: Papadopoulos
authors.forename: P
authors.initials: P
authors.lastname: Roy
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000235:genetics; D001819:Bluetongue / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D001820:Bluetongue virus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D036022:Capsid Proteins / Q000276:immunology*; D005060:Europe; D005260:Female; D014644:Genetic Variation; D005822:Genetic Vectors; D008969:Molecular Sequence Data; D058974:Phylogeography; D017422:Sequence Analysis, DNA; D012756:Sheep; D022721:Vaccines, Virosome / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014766:Viremia / Q000276:immunology / Q000517:prevention & control
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; C442520:VP2 protein, Bluetongue virus; D022721:Vaccines, Virosome; D014765:Viral Vaccines